DOYLESTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today reported financial results for the three months ended March 31, 2023 and provided a business update.

See the original post:
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations

Advancing clinical development of MT-6402, MT-8421, and MT-0169, and preclinical activities related to Bristol Myers Squibb collaboration

Visit link:
Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update

- Topline data for pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected mid-2023 –

Link:
Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights

- Timber has now Enrolled Over 60% of Patients for Pivotal TMB-001 Phase 3 ASCEND Clinical Trial -

Read more here:
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial Results

TARRYTOWN, NY, May 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today provided a business update and reported financial results for the first quarter 2023 ended March 31, 2023.

Excerpt from:
PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023

ROCKVILLE, Md., May 15, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its first quarter 2023 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update.

View post:
OpGen Reports First Quarter 2023 Financial Results and Provides Business Update

FORT WORTH, TX, May 15, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today its strategic, operational and financial results for the quarter ended March 31, 2023.

Visit link:
Sanara MedTech Inc. Announces First Quarter 2023 Results

FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of January 3, 2024 FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of January 3, 2024

Link:
Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Topline results to include biopsy results for the Phase 2 clinical study evaluating ELX-02 for the potential treatment of Alport syndrome expected in first half of 2023; meaningful protein reduction has been observed in one patient to date

Link:
Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update

WARRINGTON, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today reported financial results for the first quarter ended March 31, 2023 and provided key business updates.

Go here to see the original:
Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates

ERYTECH Provides Update on the Announced Combination with PHERECYDES

See the original post:
ERYTECH Provides Update on the Announced Combination with PHERECYDES

Significant YTD Progress in Neurology and Oncology Programs

Read more from the original source:
Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update

WARREN, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2023.

View post:
Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results

Management to host webcast/conference call today at 2:00 p.m. PT / 5:00 p.m. ET Management to host webcast/conference call today at 2:00 p.m. PT / 5:00 p.m. ET

The rest is here:
Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

U.S. OLPRUVA™ launch progressing ahead of schedule with drug-in-channel now anticipated in mid-June 2023 U.S. OLPRUVA™ launch progressing ahead of schedule with drug-in-channel now anticipated in mid-June 2023

More:
Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate Update

BRISBANE, CALIFORNIA, May 15, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced first quarter 2023 results for the period ended March 31, 2023.

More here:
GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

TORONTO, Ontario and CAMBRIDGE, Massachusetts , May 15, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced its first quarter 2023 financial results and recent highlights.

View post:
ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights

LAS VEGAS, May 15, 2023 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a leading developer and distributor of plant-based nutraceutical products for heart and brain health, reported results for the first quarter ended March 31, 2023. All comparisons are to the year-ago period unless otherwise noted.

Visit link:
Healthy Extracts Reports First Quarter 2023 Results

DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will now report financial results for the first quarter of fiscal year 2023 after the market closes on Tuesday, May 16, 2023. The Company’s management will host a conference call at 5:00 p.m. Eastern Time that same day to discuss the results and provide a business update.

Link:
Bioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023

TOKYO and CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (brand name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (A?) protofibril* antibody, for the treatment of early Alzheimer’s disease (mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD dementia) with confirmed amyloid pathology in the brain.

Original post:
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease